AR and prostate cancer: Mice that received 3 weeks of treatment with ASC-J9 showed no significant difference in appearance and had little change in serum testosterone concentrations (Supplemental Figure 5), and several studies have demonstrated that ASC-J9 can suppress several AR-mediated diseases, such as spinal and bulbar muscular atrophy neuron disease (15), prostate cancer (14), and liver cancer (17) as well as bladder cancer (13).